{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:50:55Z","timestamp":1784735455489,"version":"3.55.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T00:00:00Z","timestamp":1440460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA165998"],"award-info":[{"award-number":["T32CA165998"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>The increasing incidence of primary cutaneous B-cell lymphomas (PCBCLs) presents new challenges for clinicians. Despite advances in the clinical and pathologic characterization of PCBCL, the significance of the current staging approach as a risk profiling tool and the effect of various treatments on outcome remain unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods.<\/jats:title>\n                  <jats:p>We retrospectively reviewed patients who presented with a diagnosis of PCBCL seen at The Ohio State University between 1998 and 2012. We reviewed the initial presentation and treatment modality. We then assessed whether the treatment modality (conservative skin-directed vs. definitive radiation with or without systemic therapy), stage (T1 or \u2265T2), or histologic subtype (primary cutaneous follicle center lymphoma [PCFCL] vs. primary cutaneous marginal zone B-cell lymphoma [PCMZL]) affected the risk of recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>We identified 67 patients referred with an initial diagnosis of PCBCL. After imaging, 12 did not meet the criteria for PCBCL and were classified as having systemic B-cell lymphoma with cutaneous involvement. The remaining 55 patients included 25 with PCMZL, 24 with PCFCL, 2 with primary cutaneous large B-cell lymphoma leg type, and 4 with unclassifiable disease. According to the International Society of Cutaneous Lymphoma-European Organization for Research and Treatment of Cancer staging, 30 cases were T1 (55%), 14 T2 (25%), and 11 T3 (20%). Comparing the time to first recurrence (TFR) by indolent PCBCL subtypes, we found no difference in the recurrence risk for either stage (T1, p = .51 vs. T2\/T3, p = .30). Comparing TFR by treatment modality, we found no difference in TFR within T1 patients (p = .34) or T2\/T3 patients (p = .44).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Our limited analysis highlights the importance of complete staging at diagnosis and suggests that the treatment modality does not affect the risk of recurrence in T1 indolent PCBCL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice:<\/jats:title>\n                  <jats:p>Primary cutaneous B-cell lymphoma (PCBCL) is a rare malignancy with an increasing incidence. Clinicians must recognize the importance of a complete workup to accurately diagnose PCBCL, given the effect on prognosis and treatment. It was observed that nearly 20% of the patients who presented initially with cutaneous B-cell lymphoma were classified as having systemic B-cell lymphoma after whole body imaging. The findings from the present retrospective analysis of a single-institution cohort suggest that for early-stage indolent PCBCL, no front-line treatment strategy that decreases the risk of recurrence is obvious. No difference in the risk of recurrence between conservative skin-directed and other therapies was observed. These data support a continued need to compare front-line treatment therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0175","type":"journal-article","created":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T01:54:02Z","timestamp":1440554042000},"page":"1161-1166","source":"Crossref","is-referenced-by-count":21,"title":["Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University"],"prefix":"10.1093","volume":"20","author":[{"given":"Brad","family":"Haverkos","sequence":"first","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Tyler","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A.","family":"Gru","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca Kartono","family":"Winardi","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Frederickson","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hastings","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Elkins","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xu-Welliver","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Department of Radiation Oncology, The Ohio State University, Columbus, Ohio, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry K.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Arkansas for Medical Sciences, College of Medicine, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,8,25]]},"reference":[{"key":"2021122309355295300_B1","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"2021122309355295300_B2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.cco.0000239879.31463.42","article-title":"Primary cutaneous B-cell lymphoma: Classification and treatment","volume":"18","author":"Willemze","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"2021122309355295300_B3","doi-asserted-by":"crossref","first-page":"329.e1","DOI":"10.1016\/j.jaad.2013.06.012","article-title":"Primary cutaneous B-cell lymphomas: Part I. Clinical features, diagnosis, and classification","volume":"69","author":"Suarez","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2021122309355295300_B4","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/archderm.143.12.1520","article-title":"Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification","volume":"143","author":"Senff","year":"2007","journal-title":"Arch Dermatol"},{"key":"2021122309355295300_B5","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Prognostic factors in primary cutaneous B-cell lymphoma: The Italian Study Group for Cutaneous Lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122309355295300_B6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1524-4725.1984.tb00898.x","article-title":"Skin involvement of malignant B-cell lymphomas","volume":"10","author":"Sterry","year":"1984","journal-title":"J Dermatol Surg Oncol"},{"key":"2021122309355295300_B7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ajh.23360","article-title":"Cutaneous B-cell lymphomas: 2013 Update on diagnosis, risk-stratification, and management","volume":"88","author":"Wilcox","year":"2013","journal-title":"Am J Hematol"},{"key":"2021122309355295300_B8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clml.2013.04.011","article-title":"Aggressive behavior and elevated lactate dehydrogenase at baseline confer inferior prognosis in patients with primary cutaneous lymphoma","volume":"13","author":"Liu","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122309355295300_B9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00277-010-1083-1","article-title":"CLIPI: A new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)","volume":"90","author":"Mian","year":"2011","journal-title":"Ann Hematol"},{"key":"2021122309355295300_B10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","article-title":"TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S\u00e9zary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"2021122309355295300_B11","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: Comparison with previous classifications and identification of prognostic markers","volume":"25","author":"Senff","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122309355295300_B12","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"2021122309355295300_B13","doi-asserted-by":"crossref","first-page":"343.e1","DOI":"10.1016\/j.jaad.2013.06.011","article-title":"Primary cutaneous B-cell lymphomas: Part II. Therapy and future directions","volume":"69","author":"Suarez","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2021122309355295300_B14","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"2021122309355295300_B15","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00000478-198607000-00002","article-title":"Cutaneous follicular lymphoma","volume":"10","author":"Garcia","year":"1986","journal-title":"Am J Surg Pathol"},{"key":"2021122309355295300_B16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2230.1989.tb00875.x","article-title":"Primary cutaneous follicular centre-cell lymphoma\u2014A lymphoproliferative disease with favourable prognosis","volume":"14","author":"Pimpinelli","year":"1989","journal-title":"Clin Exp Dermatol"},{"key":"2021122309355295300_B17","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/1097-0142(19910501)67:9<2311::AID-CNCR2820670918>3.0.CO;2-0","article-title":"Primary cutaneous B-cell lymphoma: A unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases","volume":"67","author":"Santucci","year":"1991","journal-title":"Cancer"},{"key":"2021122309355295300_B18","first-page":"3637","article-title":"Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the S\u00e9zary syndrome","volume":"93","author":"Grange","year":"1999","journal-title":"Blood"},{"key":"2021122309355295300_B19","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood-2003-08-2726","article-title":"Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas","volume":"103","author":"Grange","year":"2004","journal-title":"Blood"},{"key":"2021122309355295300_B20","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","article-title":"Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis","volume":"132","author":"Vermeer","year":"1996","journal-title":"Arch Dermatol"},{"key":"2021122309355295300_B21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/10428190802064925","article-title":"Primary cutaneous B-cell lymphomas\u2014Clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL\/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S\u00e9zary syndrome","volume":"49","author":"Golling","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2021122309355295300_B22","volume-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008","edition":"4th ed"},{"key":"2021122309355295300_B23","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"Van Dongen","year":"2003","journal-title":"Leukemia"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0175","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0175","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/10\/1161\/41867588\/oncolo_20_10_1161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/10\/1161\/41867588\/oncolo_20_10_1161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T02:57:55Z","timestamp":1640314675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/10\/1161\/6399661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,25]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,8,25]]},"published-print":{"date-parts":[[2015,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0175","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,10,1]]},"published":{"date-parts":[[2015,8,25]]}}}